ResearchMoz.us include new market research report"Irritable Bowel Syndrome Global Clinical Trials Review, H1, 2015 " to its huge collection of research reports.
GlobalData's clinical trial report, “Irritable Bowel Syndrome Global Clinical Trials Review, H1, 2015"" provides data on the Irritable Bowel Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Irritable Bowel Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe.
Full Report With TOC @ http://www.researchmoz.us/irritable-bowel-syndrome-global-clinical-trials-review-h1-2015-report.html
The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Irritable Bowel Syndrome. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
Scope
Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
Listings of discontinued trials (suspended, withdrawn and terminated)
Request A Report Sample @ http://www.researchmoz.us/enquiry.php?type=sample&repid=244883
Reasons to buy
Understand the dynamics of a particular indication in a condensed manner
Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
Obtain discontinued trial listing for trials across the globe
Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
For More Information Kindly Contact:
Email: sales@researchmoz.us
WebSite:http://www.researchmoz.us/
0 comments:
Post a Comment